JCXH-221 / Immorna - LARVOL DELTA

A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine (clinicaltrials.gov) - P1 | N=73 | Completed | Sponsor: Immorna Biotherapeutics, Inc. | Recruiting ➔ Completed | Phase classification: P1/2 ➔ P1 | N=262 ➔ 73 | Trial completion date: Oct 2024 ➔ Dec 2023 | Trial primary completion date: Sep 2024 ➔ Dec 2023

Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine (clinicaltrials.gov) - P1/2 | N=262 | Recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine (clinicaltrials.gov) - P1/2 | N=262 | Not yet recruiting | Sponsor: Immorna Biotherapeutics, Inc.

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases